Observational analysis reveals precise drug screening in head and neck tumor organoids, highlighting efficiency and cost-effectiveness of microfluidic technology.
A dual-channel microfluidic chip generates stable six-step drug gradients for head and neck tumor organoids, enabling rapid, low-cost, and precise combination drug screening with results matching conventional assays.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: